Premium
Panax notoginseng Attenuates Experimental Colitis in the Azoxymethane/Dextran Sulfate Sodium Mouse Model
Author(s) -
Wen XiaoDong,
Wang ChongZhi,
Yu Chunhao,
Zhao Lei,
Zhang Zhiyu,
Matin Adiba,
Wang Yunwei,
Li Ping,
Xiao ShuYuan,
Du Wei,
He TongChuan,
Yuan ChunSu
Publication year - 2014
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5066
Subject(s) - azoxymethane , panax notoginseng , colitis , inflammatory bowel disease , medicine , pharmacology , inflammation , nitric oxide synthase , colorectal cancer , nitric oxide , gastroenterology , pathology , cancer , disease , alternative medicine
Patients suffering from inflammatory bowel disease are at a high risk of developing colorectal cancer. To assess the anticancer potential of botanicals, in this study, we evaluated the effects of Panax notoginseng on azoxymethane/dextran sulfate sodium (DSS)‐induced colitis. One week after A/J mice received azoxymethane, the animals received DSS for 8 days or were supplemented with P . notoginseng extract, at 30 or 90 mg/kg. DSS‐induced colitis was scored with the disease activity index. The severity of the inflammatory lesions was evaluated by a colon tissue histological assessment. The expression of inducible nitric oxide synthase and cyclooxygenase‐2 (COX‐2) were also explored. We observed that the effects of P . notoginseng on the reduction of colon inflammation, expressed in disease activity index score, were in a dose‐related manner ( p < 0.01). P . notoginseng inhibited the reduction of the colon length and the loss of bodyweight in dose‐related manner (all p < 0.05). The histological assessment of the colitis and inflammatory‐related immunohistochemical data also supported the pharmacological observations. Our data suggest that P . notoginseng is a promising candidate in preventing and treating colitis and inflammation‐associated colon carcinogenesis. Copyright © 2013 John Wiley & Sons, Ltd.